EXICURE
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
EXICURE
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2009-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.exicuretx.com
Total Employee:
11+
Status:
Active
Contact:
(847)673-1700
Total Funding:
105.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Luye Pharma
Luye Pharma investment in Venture Round - Exicure
HT Capital
HT Capital investment in Venture Round - Exicure
Alumni Ventures
Alumni Ventures investment in Venture Round - Exicure
Knoll Capital Management
Knoll Capital Management investment in Venture Round - Exicure
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Venture Round - Exicure
Katalyst Securities
Katalyst Securities investment in Venture Round - Exicure
David R. Walt
David R. Walt investment in Venture Round - Exicure
Tempus
Tempus investment in Venture Round - Exicure
Craig Mundie
Craig Mundie investment in Venture Round - Exicure
Mark Tompkins
Mark Tompkins investment in Venture Round - Exicure
Official Site Inspections
http://www.exicuretx.com Semrush global rank: 4.31 M Semrush visits lastest month: 2.66 K
- Host name: 115.147.96.66.static.eigbox.net
- IP address: 66.96.147.115
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803
More informations about "Exicure"
Company - Exicure, Inc. (Nasdaq:XCUR)
About Us. Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.See details»
Exicure, Inc. (Nasdaq:XCUR)
Exicure, Inc. is a biotechnology company developing nucleic acid therapies for neurological disorders and hair loss.See details»
Exicure, Inc. - Investor Relations
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss.See details»
Exicure, Inc. - Exicure, Inc. Reports Full Year 2022 Financial Results ...
Mar 27, 2023 Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated …See details»
Exicure, Inc. - Exicure, Inc. Announces Leadership Transition and ...
Feb 4, 2022 “On behalf of the Board and the Exicure organization, I would like to thank Brian, Tim, Bosun and Andy for all of their contributions to the Company and wish all of them the best …See details»
Working At Exicure: Company Overview and Culture - Zippia
Exicuretx.com. Organization Type. Public. Social Media. Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene …See details»
Contact Us - Exicure, Inc. (Nasdaq:XCUR)
Corporate Address. 2430 N. Halsted Street Chicago, IL 60614 847.673.1700 (Tel) 847.556.6411 (Fax)See details»
Exicure, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral …See details»
Exicure - Crunchbase Company Profile & Funding
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.See details»
Exicure, Inc. Announces Shareholders Approve the $8.7 Million …
2 days ago CHICAGO, December 21, 2024--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board ChangesSee details»
Exicure, Inc. - Exicure, Inc. Reports Full Year 2021 Financial Results ...
Mar 25, 2022 Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022 Continues …See details»
Exicure Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Exicure has 1 employees across 2 locations and $28.83 m in annual revenue in FY 2022. See insights on Exicure including office locations, competitors, revenue, financials, …See details»
Exicure - Overview, News & Similar companies | ZoomInfo.com
Feb 5, 2024 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), …See details»
Science and Technology - Exicure, Inc. (Nasdaq:XCUR)
Exicure's Approach. Our passion for developing the next generation of nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders starts with our …See details»
Exicure, Inc. - Exicure, Inc. Announces Adjournment of Special …
Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has …See details»
CORRECTING and REPLACING Exicure, Inc. Announces
2 days ago CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes. …See details»
CORRECTING and REPLACING - Business Wire
2 days ago Media Contact: Josh Miller 847-673-1700 [email protected] Release Summary Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports …See details»
Partnering and Licensing - Exicure, Inc. (Nasdaq:XCUR)
Exicure is actively pursuing partnership opportunities in the field of nucleic acid therapeutics. Our differentiating approach combines our automated and high-throughput nucleic acid synthesis …See details»
Exicure, Inc. - Exicure, Inc. Reports Third Quarter 2022 Financial ...
Sep 26, 2022 Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated …See details»
Exicure, Inc. Announces Shareholders Approve the $8.7
3 days ago Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special …See details»